Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In for a mill at .004. It's been a while since I've traded pennies. They are fun. But i'm always VERY WARY when I come to a forum and see BOOM, TO THE MOON, etc flying around in every other post. Shady as hell. Will be out with a decent profit. Chart looks good, imo.
Oh god. Did I stumble into a group pump? Found this on my scanner and bought in. Wish I would have checked here first. Hopefully you guys do a good job pumping this thing enough for me to exit next week.
In @ .315 a few days ago.
idk if it will fill the gap upwards. It's usually the other way around when gaps fill, downward. That said, I'm in at $1.27 and $1.10. Zacks released FCSC as a Strong Buy yesterday. Will hold into next week to see what happens.
New Filing: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9407293
This prospectus relates to up to 8,268,964 shares of our common stock, consisting of:
· 3,716,177 shares initially issued or issuable upon conversion of an aggregate of 2,527 shares of our series B convertible preferred stock issued in a private placement that closed on May 24, 2013;
· 836,610 shares issued or that may be issuable as payment for dividends on the series B convertible preferred stock, payable through December 31, 2015; and
· 3,716,177 shares initially issued or issuable upon exercise of warrants at an exercise price of $1.08 per share, subject to adjustment as provided in the warrants, which warrants were issued in the private placement.
The shares of our common stock are being registered to fulfill our contractual obligations under a registration rights agreement by and among us and the selling stockholders named in this prospectus.
The shares offered by this prospectus may be sold from time to time by the selling stockholders at prevailing market prices or prices negotiated at the time of sale. See “Plan of Distribution” and “Selling Stockholders.” The shares offered by this prospectus are issuable upon conversion of securities issued to the selling stockholders in transactions exempt from registration under the Securities Act of 1933, or Securities Act.
We will not receive any cash proceeds from the sale of shares by the selling stockholders, but to the extent that the warrants are exercised in whole or in part, we will receive payment for the exercise price. We will pay the expenses of registering these shares.
Our common stock is dually listed on the OTC Bulletin Board (OTCBB) and the OTCQB quotation systems under the symbol “GTHP.” The last reported sale price of our common stock on the OTCBB on July 3, 2013 was $0.70 per share. The selling stockholders will sell at prevailing market prices per share (as quoted on the OTCBB), at the time of sale, at fixed prices, at varying prices determined at the time of sale, or at negotiated prices.
Investing in our common stock involves a high degree of risk. These risks are described under the caption “Risk Factors” that begins on page three of this prospectus.
Neither the Securities and Exchange Commission, or SEC, nor any state securities commission has approved or disapproved of the common stock that may be offered under this prospectus, nor have any of these organizations determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Well I was in at 1.01....so 25% profit ain't bad
I'm happy with my profit taking...but I'm also kind of kicking myself right now, lol.
Jumped back into GTHP today at .705
Out at 1.26 this morning!
I see some of the pumpers from previous weeks have stopped posting. I'm really glad they started posting, that told me to sell, and sell I did (in @ .38 out at .51)! I think this has dropped back down enough for me to temporarily jump back in. We'll see on Friday.
In at 1.01
Ya they are! I'm wanting to jump back in, in the mid .60's. That is if I can get rid of my current stock in time.
Huh?? How are you going to have two golden crosses?
I miss penny stocks and pumpers. lol. So entertaining. You guys make me laugh and face palm myself at the same time. You'd do more good to post actual links to articles and facts, than spouting the nonsense you guys are. If your goal is to get plug to the leader board by having a lot of posts, you're going about it in the wrong way. If it's to dupe people into buying the stocks, your promotion skills are seriously lacking.
lol. I feel your pain. I was in GTHP for well over a year and was averaged in at .89. I just recently sold last .90 last month and seriously thought about hitting the ask at the end of the day, today...then I bought QTWW instead...
Picked up some shares at .59
Sorry, wrong board. Delete this post.
Awesome. I'm just saying blanket statements that X looks like Y, are misleading without evidence. There are link buttons and urls you can post to give your words more validity. Otherwise, all these short back to back posts just makes me think pumpers, and want to leave. Don't get me wrong, I still hold some and for my own reasons. I'm just stating my observations over the past 3 days...I've only been in for 12 days, myself.
Edit: I chose to go @ .5120 from .38. Had to lock down profits. Good luck to all. I'll watch for reentry.
I wish you guys would stops comparing this to FNMA...just sounds like pumper talk....the past few days, this board has been flooded with nonsense, pumper talk. But I appreciate the PPS raise. Thanks for helping me out with a nice profit
Oh no...you found me!
I'm holding to see what Air Liquide eventually does. I could actually foresee them buying a portion of the company, or at least some technology patents.
I agree. Lotto here. I got in at $0.38 last Friday. $.35 seems to be our short-term support line. I'll start worrying if it dips below .30, lol
What the wha.....I stop watching this stock for a few weeks and it up and changes it's name on me, lol. Scared the hell out of me when I randomly typed it into stockcharts.com while checking on other stocks. Had to come here to see what the hell happened.
Please, point that out to me! I'm in this, but come on...randomly saying a golden cross is coming tomorrow will not actually make it come. Look at the chart...we're a long ways off from a golden cross.
8-K Received Today
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8785195
(a) On August 20, 2012, the Company’s officers purchased 2,000,000 shares of Class A Common Stock. The Company’s officers have agreed not to sell any of their shares on the open market until at least June 30, 2013.
Edit: lol...this whole post should be bolded!
Guided Therapeutics and FDA Agree on Plan for LuViva(R) Advanced Cervical Scan PMA
Company to amend PMA filing at FDA's direction
NORCROSS, Ga., Jul 25, 2012 (BUSINESS WIRE) -- Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it met with the Food and Drug Administration (FDA) on July 20, 2012. The company believes the meeting was very positive and plans to work with FDA to finalize the path forward to gain premarket approval (PMA) for the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, instantly and at the point of care.
The preliminary plan calls for the company to file a PMA amendment using existing clinical data to address the agency's questions stemming from its January 20, 2012 "not approvable" letter. The company maintained at the meeting with the FDA that the new data analysis to be included in the amended PMA demonstrates the clinical benefit of LuViva in light of new cervical cancer screening guidelines adopted earlier this year.
"We are pleased with both the tenor and substance of the meeting with FDA and believe we have a good plan to move the PMA process forward through what we hope will be a quick review and approval for LuViva," said Mark L. Faupel, Ph.D., President and CEO of Guided Therapeutics. "We believe that once approved, LuViva will have a very positive impact on the U.S. healthcare system by improving the standard of care for the early detection of cervical disease, and providing women and doctors the first test with instant results."
LuViva has been under FDA PMA review since September 23, 2010. The company received a "not approvable" letter for the product on January 20, 2012. In May, 2012 the company requested a meeting with the agency, and suggested a path for possible approval to which the FDA was receptive. After a PMA amendment is submitted, the FDA has 180 days during which it can respond.
In addition to the recently announced CE Mark, LuViva has marketing approval from Health Canada. Guided Therapeutics was awarded ISO 13485 certification in January, 2011. The company continues to anticipate a launch in international markets later in 2012.
About LuViva(R) Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva(R) Cervical Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company's first planned product is the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics has also entered into a partnership with Konica Minolta to develop a non-invasive test for Barrett's Esophagus using the technology platform. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva(R) Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the exchange offer, as described in the Offer to Exchange, as well as those related to: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and subsequent quarterly reports.
SOURCE: Guided Therapeutics, Inc.
CONTACT:
Investors: Cameron Associates Alison Ziegler, 212-554-5469 or Guided Therapeutics Bill Wells, 770-242-8723 Ext. 241
Copyright Business Wire 2012
-0-
KEYWORD: United States
North America
Georgia
INDUSTRY KEYWORD: Health
Medical Devices
FDA
SUBJECT CODE: Product/Service
Breaking 400k Volume. GTHP is certainly trying!
Damn straight. 125k bought in the first 15 minutes!
Guided Therapeutics Notified of CE Mark Approval for LuViva(R) Advanced Cervical Scan
8:05a ET July 18, 2012 (Business Wire)
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has received notification that CE Mark approval has been granted for LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, instantly and at the point of care.
The CE Mark is required to sell products in the 27 nations that comprise the European Union (EU). There are about 146 million women who are targeted by existing or planned cervical cancer screening programs in EU member states, according to the European Cancer Observatory.
"The notification of CE Mark for LuViva is a significant milestone for the company and allows us to begin our European launch later this year, as planned," said Mark L. Faupel, Ph.D., president and CEO of Guided Therapeutics. "We believe that together with our distributors, we have a tremendous opportunity to improve the detection of cervical disease, reduce false positives and unnecessary biopsies, and provide significant savings to healthcare systems throughout Europe."
"Notification of the CE Mark and previously announced Health Canada approval for LuViva further validates the product and our ability to manufacture to the highest standards. We expect the CE Mark award will generate more demand for the product and open opportunities in markets outside the EU as well. In addition to the more than 20 countries already covered by distribution agreements, we plan to expand our network to additional countries in Europe, Latin America and Asia and having the CE Mark should accelerate those efforts," Dr. Faupel added.
Today's CE Mark notification is the first of two expected for LuViva. A second CE Mark application is expected to be filed later this year to comply with updated European medical device standards and to include design improvements. The company also must continue to pass annual ISO audits of its quality system in order to maintain the CE Mark on its products. The company has passed two consecutive ISO audits, the last being in January of 2012.
In addition to the CE Mark, LuViva has marketing approval from Health Canada and remains under U.S. Food and Drug Administration premarket approval review. Guided Therapeutics was awarded ISO 13485 certification in January, 2011.
The study used to support LuViva's CE Mark application was the multi-center U.S. pivotal trial, in which 1,607 women at risk for developing cervical disease were evaluated. In this patient population, LuViva was able to detect cervical cancer up to two years earlier than the Pap test, human papillomavirus (HPV) test, colposcopy and biopsy. LuViva detected 86.3 percent of the cervical disease cases that had been missed by Pap, HPV tests and biopsy. LuViva would have reduced the number of unnecessary biopsies by about 40 percent. LuViva is initially intended as a follow-up test after a positive Pap result.
About LuViva(R) Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva(R) Cervical Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company's first planned product is the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics has also entered into a partnership with Konica Minolta to develop a non-invasive test for Barrett's Esophagus using the technology platform. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva(R) Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the exchange offer, as described in the Offer to Exchange, as well as those related to: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and subsequent quarterly reports.
SOURCE: Guided Therapeutics, Inc.
Investors:
Cameron Associates
Alison Ziegler, 212-554-5469
or
Guided Therapeutics
Bill Wells, 770-242-8723 Ext. 241
Hell Yeah! I doubled down at $.70 last week, too!
Hey. Been out. Gonna try and get mod approval shortly.
Steady as she goes!
$.94 I'm looking to add more next week if we get a mid .80s pullback. Looking for us to break $1 withing two weeks.
Idk...but the volume sure has been picking up over the week! News last week and the 8-k followed this week. Just a good company :)
Great news! "The CE Mark is required to market LuViva in the 27 nations that comprise the EU."